<DOC>
	<DOCNO>NCT01311505</DOCNO>
	<brief_summary>This study do demonstrate bioequivalence rifampicin component Myrin© 2 Fixed-Dose Combination Tablet ( contain 75 mg isoniazid 150 mg rifampicin , Pfizer Inc ) equivalent dose reference Rimactane® capsule ( contain 300 mg rifampicin , Novartis Sandoz ) healthy Filipino male subject . This study also aim determine safety tolerability Myrin© 2 tablet Rimactane® capsule subject .</brief_summary>
	<brief_title>Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination ( Rifampicin+Isoniazid , Myrin© 2 ) And The Reference Drug ( Rifampicin , Rimactane® )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Healthy male subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 21 drinks/week ( 1 drink = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) hard liquor ) within 6 month screen . Treatment investigational drug within 3 month ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . History previous treatment TB suspect suffer TB . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal medication , herbal supplement hormone replacement therapy must discontinue 28 day prior first dose study medication . As exception , acetaminophen / paracetamol may use dos less 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation approximately 1 pint ( 500 ml ) within 56 day prior dose . A history hypersensitivity study medication related substance , ingredient use study drug formulation . Unwilling unable comply Lifestyle guideline describe protocol . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Recent history diarrhea ( 2 week ) . Recent use oral ( 2 week ) IV ( 23 month ) antibiotic assure normal bowel flora study start .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>bioequivalence ; rifampicin</keyword>
</DOC>